SALAROGLIO, Iris Chiara
 Distribuzione geografica
Continente #
NA - Nord America 4.290
AS - Asia 3.741
EU - Europa 2.785
SA - Sud America 349
AF - Africa 94
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 4
Totale 11.292
Nazione #
US - Stati Uniti d'America 4.112
CN - Cina 1.537
IT - Italia 1.030
SG - Singapore 1.020
BR - Brasile 252
VN - Vietnam 234
FR - Francia 222
DE - Germania 212
HK - Hong Kong 209
SE - Svezia 201
AT - Austria 179
IE - Irlanda 169
JP - Giappone 152
GB - Regno Unito 142
FI - Finlandia 119
IN - India 110
KR - Corea 106
CA - Canada 87
MX - Messico 75
PL - Polonia 73
NL - Olanda 70
ES - Italia 67
ID - Indonesia 67
TW - Taiwan 61
UA - Ucraina 60
BE - Belgio 53
BD - Bangladesh 43
AR - Argentina 36
TR - Turchia 32
RU - Federazione Russa 30
AU - Australia 28
EG - Egitto 25
IR - Iran 25
PT - Portogallo 25
CH - Svizzera 22
CO - Colombia 22
IQ - Iraq 22
CZ - Repubblica Ceca 20
DK - Danimarca 20
PK - Pakistan 20
GR - Grecia 19
EC - Ecuador 16
ZA - Sudafrica 15
LB - Libano 13
MA - Marocco 13
NO - Norvegia 12
IL - Israele 11
MO - Macao, regione amministrativa speciale della Cina 11
RO - Romania 11
SA - Arabia Saudita 11
CL - Cile 10
MY - Malesia 10
SN - Senegal 9
PH - Filippine 8
HU - Ungheria 7
UZ - Uzbekistan 7
VE - Venezuela 7
KE - Kenya 6
TH - Thailandia 6
AM - Armenia 5
KZ - Kazakistan 5
DO - Repubblica Dominicana 4
DZ - Algeria 4
JO - Giordania 4
LT - Lituania 4
MD - Moldavia 4
NG - Nigeria 4
AZ - Azerbaigian 3
LV - Lettonia 3
NA - Namibia 3
PE - Perù 3
PY - Paraguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BQ - ???statistics.table.value.countryCode.BQ??? 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
JM - Giamaica 2
MK - Macedonia 2
MU - Mauritius 2
NP - Nepal 2
SC - Seychelles 2
SV - El Salvador 2
TN - Tunisia 2
AD - Andorra 1
AO - Angola 1
AP - ???statistics.table.value.countryCode.AP??? 1
AW - Aruba 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GN - Guinea 1
GT - Guatemala 1
Totale 11.280
Città #
Singapore 603
San Jose 413
Ashburn 376
Beijing 276
Chandler 252
Turin 236
Santa Clara 208
Torino 206
Vienna 167
Fairfield 166
Dublin 165
Dallas 140
Houston 119
Woodbridge 99
Ann Arbor 94
Guangzhou 89
Los Angeles 89
Seoul 84
Seattle 82
Hong Kong 81
Wilmington 78
New York 76
Hefei 71
Helsinki 71
Tokyo 65
Cambridge 64
Dearborn 64
Ho Chi Minh City 63
Shanghai 63
Nyköping 58
The Dalles 57
Hangzhou 55
Lauterbourg 50
Nanjing 50
Hanoi 48
Milan 48
Munich 48
Pisa 48
Jakarta 47
Columbus 46
Redwood City 44
Buffalo 42
São Paulo 39
Warsaw 39
Princeton 38
Central 37
Taipei 37
Frankfurt am Main 35
Boardman 33
Brussels 33
Council Bluffs 32
Medford 31
Wuhan 31
Changsha 30
Fremont 30
Villeurbanne 28
Amsterdam 27
Bengaluru 26
Boston 25
London 25
Orem 25
Paris 25
Jacksonville 24
Shenzhen 24
Toronto 22
Lappeenranta 21
Nuremberg 21
Jinan 20
Montreal 20
Rome 20
Chengdu 19
Chongqing 19
Dong Ket 18
San Diego 18
Tianjin 18
Shenyang 17
Silver Spring 17
Chicago 16
Mexico City 16
Stockholm 16
Phoenix 15
Las Vegas 14
Brescia 13
Collegno 13
Madrid 13
Mumbai 13
Naples 13
Osaka 13
Suzhou 13
Washington 13
Xian 13
Cairo 12
Chennai 12
Denver 12
Redondo Beach 12
Benito Juarez 11
Brno 11
Brooklyn 11
Florence 11
Istanbul 11
Totale 6.422
Nome #
Impact of cancer metabolism on therapy resistance – Clinical implications 1.059
Hypoxia as a driver of resistance to immunotherapy 1.019
Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5 623
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment 554
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma 397
Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors 356
Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma 354
Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3-signalling. 347
PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy 332
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer 251
The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma 251
ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer 232
Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells 213
P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors 203
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells 201
Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells 197
Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: preliminary study for glioma treatment 192
Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma 191
The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells. 189
Temozolomide down-regulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/GSK3/β-catenin pathway 188
Autocrine 17-β-estradiol/estrogen receptor-α loop determines the response to immune-checkpoint inhibitors in non-small cell lung cancer 175
New tetrahydroisoquinoline derivatives overcome pgp activity in brain-blood barrier and glioblastoma multiforme in vitro 173
Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma 169
TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer 167
Methotrexate-Loaded Solid Lipid Nanoparticles: Protein Functionalization to Improve Brain Biodistribution 167
SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma 166
Plant-Derived Trans-β-Caryophyllene Boosts Glucose Metabolism and ATP Synthesis in Skeletal Muscle Cells through Cannabinoid Type 2 Receptor Stimulation 160
Dysregulation of FLVCR1a-dependent mitochondrial calcium handling in neural progenitors causes congenital hydrocephalus 157
Pyruvate Treatment Restores the Effectiveness of Chemotherapeutic Agents in Human Colon Adenocarcinoma and Pleural Mesothelioma Cells 155
Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons 154
Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma 145
Blood-brain barrier permeability increases with the differentiation of glioblastoma cells in vitro 143
Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer 136
TARGETING THE CXCR4 DOWNSTREAM SIGNALLING PATHWAYS TO REVERSE MICROENVIRONMENT PROTECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 124
GIFC-2018 - BOOK OF ABSTRACTS 123
Naked and Decorated Nanoparticles Containing H2S-Releasing Doxorubicin: Preparation, Characterization and Assessment of Their Antitumoral Efficiency on Various Resistant Tumor Cells 122
Human and canine osteosarcoma cell lines: How do they react upon incubation with calcium phosphate-coated lipid nanoparticles carrying doxorubicin and curcumin? 119
Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance? 119
Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy 117
The CXCR4 downstream signaling pathways in chronic lymphocytic leukemia: a target to reverse microenvironment protection 115
TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 113
Temozolomide epigenetically down-regulates Wnt3a-dependent signaling and P- glycoprotein in glioblastoma stem cells 108
TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 108
Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma 98
A novel combinatory treatment against a CDDP-resistant non-small cell lung cancer based on a Ruthenium(II)-cyclopentadienyl compound 92
Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma 87
Thermomagnetic Resonance Effect of the Extremely Low Frequency Electromagnetic Field on Three-Dimensional Cancer Models 85
Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression 83
Enhancing pancreatic ductal adenocarcinoma (PDAC) therapy with targeted carbon nano-onion (CNO)-mediated delivery of gemcitabine (GEM)-derived prodrugs 75
Fighting Multidrug Resistance with Ruthenium-Cyclopentadienyl Compounds: Unveiling the Mechanism of P-gp Inhibition 72
Targeted Self-Emulsifying Drug Delivery Systems to Restore Docetaxel Sensitivity in Resistant Tumors 72
Smart hyaluronated micelles to enhance a gemcitabine prodrug efficacy 69
Tailoring the Composition of HA/PEG Mixed Nano-Assemblies for Anticancer Drug Delivery 65
B/N-doped carbon nano-onions as nanocarriers for targeted breast cancer therapy 62
The blood-brain barrier/glioblastoma stem cells interaction is a key factor determining tumor chemoresistance: new therapeutic strategies to improve the pharmacological treatment of glioblastoma multiforme 58
Totale 11.502
Categoria #
all - tutte 31.937
article - articoli 0
book - libri 0
conference - conferenze 2.142
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.079


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202175 0 0 0 0 0 0 0 0 0 0 0 75
2021/2022742 54 31 34 90 30 33 41 43 33 62 167 124
2022/20231.175 92 74 51 92 117 205 98 100 139 54 60 93
2023/20241.277 115 129 92 104 82 160 125 88 38 126 107 111
2024/20252.422 64 130 118 162 424 180 162 205 261 150 280 286
2025/20263.424 352 319 246 390 411 163 472 146 308 352 177 88
Totale 11.502